New Hampshire House Lets Marijuana Legalization And Psilocybin Therapy Bills Die Without A Vote

New Hampshire marijuana legalization stalls as the House lets weed and psilocybin bills die without a vote. Picture Concord on a slate-gray morning. The statehouse hums. Then, like a bartender calling last call before you get your order in, lawmakers adjourn and leave key drug policy reform on the cutting-room floor. No floor votes. No lifelines. Just bills—one to put adult-use legalization on the ballot, another to legalize low-level cannabis possession, and a third to allow medical psilocybin therapy—left to wither against a hard deadline. In a region where cannabis policy reform has become a kind of New England sport, New Hampshire still plays by its own slower, more suspicious rules. That friction defines the moment: the push and pull between Granite State caution and a shifting national landscape where rescheduling, medical access, and civil rights are recalibrating the definition of “legal cannabis revenue” and the future of the New Hampshire cannabis market.

CACR 19 was the headline act that never took the stage. The proposed constitutional amendment would have let voters decide whether adults 21 and older should be allowed to possess a “modest amount” of cannabis for personal use—no retail architecture, no possession limits etched into granite, just a principle carved into the state’s charter. Committee leaders said no, calling it constitutionally reckless, a federal trap that could collide with gun rights and federal employment rules. A last-minute motion to elevate the measure for debate failed by a lopsided tally. Supporters argued the obvious: New Hampshire residents consistently poll in favor of legalization, and deferring specifics to statute keeps the constitution clean. Still, the gavel fell, and the question never reached the floor. For the policy purists, the paper trail remains: see the state’s capsule for CACR 19 via the General Court’s tracker at this official bill page.

The second cannabis piece, HB 1235-FN, offered a pared-down route: allow adults to possess up to 2.5 ounces of flower and 10 grams of concentrates, skip the retail gauntlet, and end the low-level criminalization that has outlived its logic. The committee’s majority cited workplace harms and public safety, pointing to neighboring states for data—rising workers’ comp claims, more industrial accidents among users, a bump in road fatalities—then returned to that deeper fear of federal crossfire: a state “right” that could cost security clearances and jobs in the defense sector. Critics called those outcomes speculative and overstated. Context matters, they said, because enforcement patterns, employer policies, and impairment testing all blur the lines between use and risk. Another legalization bill with a full commercial framework and relief for past offenses cleared the House earlier this year, only to die in the Senate. Layer in a looming gubernatorial veto threat, and you get a familiar picture: a state inching forward and then double-backing. Meanwhile, Washington’s slow shuffle toward Schedule III reminds us that reclassification isn’t a finish line so much as a mile marker—see Marijuana Rescheduling Is A ‘Transitional’ Step That Must Be Followed By Banking, Commerce And Justice Reforms, New Analysis Says—and New Hampshire’s caution reads like a hedge against federal ambiguity.

On the psychedelic front, HB 1796-FN aimed straight at the ache that modern medicine still can’t reach: treatment-resistant depression, PTSD, substance use disorder, end-of-life anxiety. The bill would have allowed psilocybin therapy in supervised settings, with screening, facility security, rescue meds on site, and oversight by Health and Human Services. Fees and taxes would have seeded a therapeutic fund for research and program expansion. Supporters pitched it as harm reduction with a heartbeat—a regulated option for people who’ve tried everything else. The majority stamped it inexpedient, warning of staffing costs, nascent clinical know-how, and evidence still early in translation from trials to clinics. A separate bipartisan psilocybin medical bill has inched forward and awaits more number-crunching, so the door isn’t fully closed. If you’re tracking how patient access can narrow the gap between statute and suffering, compare this to how another state threaded the needle for vulnerable patients: Delaware Senate Passes Bill To Let Terminally Ill Patients Use Medical Marijuana In Hospitals. For the official breadcrumb trail on New Hampshire’s shelved psychedelic bill, the General Court’s page for HB 1796 sits here: formal docket link.

This is the paradox of New Hampshire’s cannabis and psychedelics moment: the House has shown flashes of courage, the Senate and governor keep their powder dry, and voters who lean pro-legalization watch their will stall out in committee rooms. Culture sprints ahead—artists, patients, veterans, and entrepreneurs already live in the future—while policy inches through a maze of constitutional scruples and federal-state contradictions. Consider how Congress is now debating whether people with past drug convictions deserve a fair shot at housing; the signal is shifting toward dignity, as captured in New Bipartisan Congressional Bill Would Prevent Housing Discrimination Against People Convicted Of Marijuana And Other Drug Offenses. Or take the trademark office telling a rap icon he can’t brand a lyric that everyone already owns, because cannabis still lives in a legal gray-zone; it’s a parable for how law chases culture with its shoelaces untied—see Feds Deny Snoop Dogg Request To Trademark ‘Smoke Weed Everyday’ Because Marijuana Is Illegal And Song Lyric Is Too Popular. New Hampshire can keep its chin up and its arms crossed, but the tide is moving. And if you’re mapping this shifting coastline and wondering how compliant THCA fits into your own journey, take a quiet spin through our curated selections at https://thcaorder.com/shop/.